# Neurology (multiple sclerosis) Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Barbara Jordan (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML030-SYN
- Date: 2026-03-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Kenji Watanabe, MD
- Calendar frame: modern shifted

- Requested by: Evangeline Moss, MD

## Reason for consultation

Multiple sclerosis diagnosed elsewhere in a 44-year-old professor and public speaker who walks with a cane, with records of the original evaluation not available. Please confirm and classify the disease on the MRI booked for the morning of your visit, and advise on disease-modifying therapy, its screening and monitoring, vaccination, symptom care and MRI follow-up. **S**

## History

Ms. Jordan, a 44-year-old professor and public speaker, is seen at the request of Dr. Moss. She was told years ago that she had multiple sclerosis; the records are not available. She describes slowly worsening walking over several years, needing a cane for some time, with no attack of new symptoms over days that then recovered. She has leg stiffness, afternoon fatigue, heat sensitivity, urinary urgency and nocturia, and no visual loss or double vision. She has had steroid courses in the past and no disease-modifying therapy. She wants to know whether a treatment can slow the disease, and wants to keep teaching and speaking. **S**

## Examination

| System | Finding |
|---|---|
| General | Well; blood pressure 122/76 |
| Cranial nerves | Visual acuity 20/20 in each eye; no relative afferent pupillary defect; full eye movements without nystagmus |
| Motor | Hip flexor strength 4 out of 5 on both sides; modified Ashworth 2 in both legs |
| Reflexes | Brisk in the legs with extensor plantar responses |
| Sensory | Reduced vibration sense at the toes |
| Gait | Spastic paraparetic gait with a cane; EDSS 6.0; timed 25-foot walk 11.0 seconds |

BP 122/76 mmHg; pulse 74 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 84.2 kg; BMI 28.1 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Moss's intake note and results: blood count, kidney and liver tests, TSH, vitamin B12 and immunoglobulins normal; 25-hydroxyvitamin D 17 ng/mL; JC virus antibody index 0.14, negative. Results since intake: hepatitis B surface antigen, core antibody and surface antibody negative; varicella IgG and measles, mumps and rubella IgG positive; tuberculosis blood test, HIV and hepatitis C negative. MRI this morning, brain with gadolinium: fourteen T2 lesions, periventricular, juxtacortical, and infratentorial in the pons and left middle cerebellar peduncle, with one enhancing right periventricular lesion. Cervical and thoracic spine: three cord lesions at C3, C5 and T6, each shorter than two segments, with no compression. 

## Assessment

1. **Active primary progressive multiple sclerosis** (G35.B1). More than a year of gradually worsening disability without relapses, with T2 lesions in characteristic brain regions and two or more spinal cord lesions, meets the 2017 McDonald criteria for primary progressive multiple sclerosis without the need for spinal fluid. The enhancing lesion shows inflammatory activity, so the disease is active. B12, thyroid and HIV results and the absence of cord compression exclude the main mimics. At 44, still walking with a cane, with an enhancing lesion, she is the kind of patient most likely to benefit from therapy. **S**
2. **Spastic gait and fall risk** (R26.89). Spasticity contributes to her slowness and stiffness; strength is fairly preserved, so a careful baclofen titration should not weaken her. **S**
3. **Neurogenic bladder** (N31.9). Urgency with a low residual; safe to treat with a bladder-relaxing medicine, preferably one without anticholinergic effects on concentration. **S**

## Recommendations

1. Ocrelizumab, the therapy with evidence for primary progressive multiple sclerosis: 300 mg intravenously on day 1 and day 15, then 600 mg every 6 months, with methylprednisolone 100 mg, an antihistamine and acetaminophen beforehand and at least one hour of observation; twice-yearly infusions suit her teaching and travel.
2. Before the first dose: she is not infected with hepatitis B but not immune, so hepatitis B vaccine; PCV20, recombinant zoster vaccine (two doses, the second after about a month), and Tdap; inactivated vaccines at least two weeks before the first dose and live vaccines at least four weeks before (none needed, as she is immune to varicella and measles); confirm no active infection on each infusion day.
3. Monitoring: blood count with lymphocytes, liver tests and immunoglobulins before each dose; hepatitis B surface antibody after the series; prompt review of infections, persistent diarrhea or new neurological symptoms; standard breast cancer screening; no live vaccines during treatment; seasonal influenza and COVID-19 vaccines, ideally at least two weeks before an infusion.
4. MRI: a re-baseline brain MRI three to six months after the first dose, then yearly, on the same scanner where possible and without routine gadolinium; spinal MRI only for new spinal symptoms.
5. Spasticity: baclofen 5 mg three times a day, increasing to 10 mg three times a day once tolerated, with daily stretching and physical therapy; gabapentin is the second choice if baclofen fails.
6. Bladder: mirabegron 25 mg daily with timed voiding and a blood pressure check at each visit.
7. Fatigue and heat: pacing, morning teaching where she chooses, cooling garments and air conditioning, and aerobic exercise in cool water; no fatigue medicine for now.
8. Relapse plan: new or worsening symptoms lasting more than 24 hours without fever or heat mean a same-day call; check for urinary infection first; heat or infection can bring back old symptoms for hours without new disease activity.
9. Multiple sclerosis neurology review after the re-baseline MRI and then every six months.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Moss, who sees her the same day. The plan was explained to Ms. Jordan, who agreed and decides who else receives this note; her reproductive plans were discussed privately and recorded in the confidential part of the chart. **S**

## Follow-up

Review after the re-baseline MRI, about seven months from now, then every six months; Dr. Moss continues primary care, vaccination and monitoring between visits. **S**

## Guideline basis

- Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018), American Academy of Neurology (Neurology)
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (Thompson AJ, et al.; PMID 29275977) (2017), International Panel on Diagnosis of Multiple Sclerosis (Lancet Neurology)
- 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (Wattjes MP, et al.; PMID 34139157) (2021), MAGNIMS, CMSC and NAIMS (Lancet Neurology)
- Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis (Farez MF, et al.; PMID 31462584) (2019), American Academy of Neurology (Neurology)
- OCREVUS (ocrelizumab) injection, prescribing information (2026), U.S. National Library of Medicine, DailyMed (Genentech label)
- Multiple sclerosis in adults: management (NG220) (2022), National Institute for Health and Care Excellence
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention
